Incidence of Opioid Overdose Among Patients Using ER/LA Opioid Analgesics Before and After Implementation of the Class-Wide Opioid Risk Evaluation and Mitigation Strategy
Received 13 June 2019
Accepted for publication 24 December 2019
Published 16 January 2020 Volume 2020:13 Pages 157—169
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Michael A Überall
Daina B Esposito, 1 M Soledad Cepeda, 2 Crystal N Holick, 1 Caitlin Knox, 1 Vibha CA Desai, 1 Nianya Liu, 1 Shiva-Krishna Vojjala, 1 Jennifer G Lyons, 1 Gregory P Wedin, 3 Stephan Lanes 1 On Behalf of the REMS Program Companies Metrics Subteam
1HealthCore, Inc, Andover, MA, USA; 2Janssen Research and Development, Titusville, NJ, USA; 3Upsher-Smith Laboratories, LLC, Maple Grove, MN, USA
Correspondence: Stephan Lanes
Safety and Epidemiology, HealthCore, Inc., 300 Brickstone Square, 8th Floor, Suite 801A, Andover, MA 01810, USA
Tel +1 302-384-0673
Fax +1 978-247-6650
Introduction: The United States (US) Food and Drug Administration (FDA) required a Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics on 09 July 2012.
Methods: This study compared the incidence of opioid overdose before (July 2010-June 2012) and after (July 2013-September 2016) the initiation of the Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics. We identified patients with ≥ 1 ER/LA opioid dispensing in either time period in national data from the HealthCore Integrated Research DatabaseSM (HIRD) and in United States (US) Medicaid claims data from four states. We described each population, calculated the incidence rate (IR) of opioid overdose, and assessed crude and propensity score adjusted incidence rate ratios (IRR) comparing the overdose rate after vs before implementation of the REMS.
Results: A total of 121,229 commercially insured and 11,488 Medicaid patients were included in the analysis. Rates of overdose were substantially higher in Medicaid patients than in the commercially insured patients (IR 192.0, 95% confidence interval [CI] 162.60– 225.18 versus 102.60, 95% CI 93.0– 112.93 in the active period). The IRRs for opioid overdose were 1.01 (95% CI 0.87– 1.17) in the commercially insured population and 0.70 (95% CI 0.52– 0.93) in Medicaid.
Conclusion: This leveling off of overdose rates among commercially insured patients and decline among Medicaid patients is encouraging, but it is difficult to disentangle the specific impact of the REMS from many other ongoing initiatives with similar goals.
Keywords: opioid, overdose, REMS, Medicaid, claims
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]